2. Academic Validation
  3. Proteolysis targeting chimeric-based technology in myeloma and lymphoma

Proteolysis targeting chimeric-based technology in myeloma and lymphoma

  • Mol Cancer Ther. 2026 Jan 2. doi: 10.1158/1535-7163.MCT-25-1148.
Adrian Bogdan Tigu 1,  Andrei Ivancuta 2,  Ciprian Tomuleasa 3,  Madalina Nistor 4,  David Kegyes 1,  Diana Cenariu 1,  Raluca Munteanu 5,  Anca Dana Buzoianu 2,  Hermann Einsele 6,  Massimo Federico 7,  Sebastian Kobold 8,  Diana Gulei 9,  Aaron Ciechanover 10
Affiliations

Affiliations

  • 1 Research Center for Advanced Medicine - MedFUTURE Cluj-Napoca Romania.
  • 2 Iuliu Hațieganu University of Medicine and Pharmacy Cluj-Napoca Romania.
  • 3 Iuliu Hatieganu University of Medicine and Pharmacy Cluj Napoca Romania.
  • 4 Iuliu Hațieganu University of Medicine and Pharmacy Romania.
  • 5 Iuliu Hatieganu University of Medicine and Pharmacy Romania.
  • 6 University Hospital Würzburg Würzburg Germany.
  • 7 University of Modena and Reggio Emilia Italy.
  • 8 Deutschen Konsortium für Translationale Krebsforschung Germany.
  • 9 Iuliu Hatieganu University of Medicine and Pharmacy Cluj-Napoca Romania.
  • 10 The Rappaport Faculty of Medicine and Research Institute, Technion-Israel Institute of Technology Haifa Israel.
PMID: 41481115 DOI: 10.1158/1535-7163.MCT-25-1148
Abstract

Proteolysis-targeting chimeras (PROTACs) leverage the ubiquitin-proteasome system to selectively degrade oncogenic proteins, including such previously seen as undruggable. Recent preclinical studies indicate that PROTACs may come as novel therapeutic strategy in lymphoma and myeloma. Indeed, preclinically, PROTACs have high efficacy and remarkable selectivity, favorable safety profile and lower toxicity compared to conventional therapies. Their catalytic, reusable mechanism enables drug dosing and offers the perspective of a long-term low dose treatment. PROTACs demonstrated their ability to overcome drug resistance by targeting and degrading overexpressed or mutant proteins, which are responsible for refractory disease. This review aims to offer a comprehensive evaluation of the current existing PROTACs that have been tested in Lymphoma and Myeloma, to highlight the need for drug optimization and further translational research that could translate PROTACs to clinical trials.

Figures
Products